Royal Marsden NHS Foundation Trust

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Private, Subsidiary

Employees: -

Market Cap: -

Website: http://www.royalmarsden.nhs.uk

Clinical Trials

A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)

Phase 2

Conditions: Renal Cell Carcinoma

Interventions: Drug: nivolumab

First Posted Date: 2015-05-18

Last Posted Date: 2018-03-26

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 19

Registration Number: NCT02446860

Locations: 🇬🇧
The Royal Marsden NHS Foundation Trust, London, United Kingdom

A Phase I, First in Man Study to Evaluate the Safety and Tolerability of a panRAF Inhibitor (CCT3833/BAL3833)in Patients With Solid Tumours

Phase 1

Completed

Conditions: Cancer
Melanoma

Interventions: Drug: CCT3833

First Posted Date: 2015-05-07

Last Posted Date: 2019-06-12

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 31

Registration Number: NCT02437227

Locations: 🇬🇧
Christie NHS Foundation Trust, Manchester, Greater Manchester, United Kingdom
🇬🇧
Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom

Phase I Trial of VS-6766 Alone and in Combination With Everolimus

Phase 1

Recruiting

Conditions: Lung Cancer
Solid Tumours
Ovarian Cancer
Multiple Myeloma

Interventions: Drug: VS-6766
Drug: Everolimus

First Posted Date: 2015-04-03

Last Posted Date: 2024-03-21

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 104

Registration Number: NCT02407509

Locations: 🇬🇧
Guy's and St Thomas' Hospital, London, United Kingdom
🇬🇧
Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
🇬🇧
Gynaecological Unit - Royal Marsden NHS Foundation Trust, London, United Kingdom

PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib

Phase 1

Conditions: Breast Cancer
Advanced Solid Tumours

Interventions: Drug: Palbociclib + Taselisib / Pictilisib

First Posted Date: 2015-03-17

Last Posted Date: 2019-11-19

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 93

Registration Number: NCT02389842

Locations: 🇬🇧
The Royal Marsden NHS Foundation Trust, London, United Kingdom
🇬🇧
The Christie NHS Foundation Trust, Manchester, United Kingdom

Phase I Trial of ONX-0801 Once Weekly or Alternate Weekly

Phase 1

Completed

Conditions: Solid Tumours

Interventions: Drug: ONX-0801

First Posted Date: 2015-02-10

Last Posted Date: 2021-03-09

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 111

Registration Number: NCT02360345

Locations: 🇬🇧
The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom

Trial of Olaparib in Combination With AZD5363 (ComPAKT)

Phase 1

Completed

Conditions: Advanced Cancer

Interventions: Drug: olaparib
Drug: AZD5363

First Posted Date: 2015-01-14

Last Posted Date: 2020-02-05

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 60

Registration Number: NCT02338622

Locations: 🇬🇧
Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom
🇬🇧
Northern Institute for Cancer, Freeman Hospital, Newcastle, Newcastle upon Tyne, United Kingdom

The Use of 3D Surface Imaging in the Objective Assessment of Breast Conserving Therapy

Conditions: Breast Cancer

Interventions: Other: 3D surface imaging using a non portable and portable camera
Other: 2D photography
Other: Applanation Tonometry

First Posted Date: 2014-12-02

Last Posted Date: 2020-10-22

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 346

Registration Number: NCT02304614

Locations: 🇬🇧
The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

Tissue Collection for Biomarkers Determining Resistance to Ibrutinib

Conditions: Chronic Lymphocytic Leukaemia
Mantle Cell Lymphoma

First Posted Date: 2014-10-17

Last Posted Date: 2014-10-17

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 120

Registration Number: NCT02267590

Locations: 🇬🇧
The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom

PPALM-Palm Oil and Pentoxifylline Against Late Morbidity

Phase 2

Completed

Conditions: Long-term Adverse Effects of Radiotherapy for Pelvic Cancer

Interventions: Drug: Tocovid SupraBio plus pentoxifylline
Drug: Matching placebos

First Posted Date: 2014-09-03

Last Posted Date: 2019-12-23

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 62

Registration Number: NCT02230800

Locations: 🇬🇧
The Royal Marsden NHS Foundation Trust, London, United Kingdom

Phase I Study to Assess Safety of AZD6738 Alone and in Combination With Radiotherapy in Patients With Solid Tumours

Phase 1

Active, not recruiting

Conditions: Solid Tumour Refractory to Conventional Treatment

Interventions: Drug: AZD6738
Radiation: Palliative radiotherapy

First Posted Date: 2014-08-22

Last Posted Date: 2023-10-10

Lead Sponsor: Royal Marsden NHS Foundation Trust

Target Recruit Count: 87

Registration Number: NCT02223923

Locations: 🇬🇧
Guys and St Thomas' NHS Foundation Trust, London, United Kingdom
🇬🇧
University College Hospital, London, United Kingdom
🇬🇧
Royal Marsden Hospital, London, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy